



19 September 2018

## ASX Announcement

### Share Purchase Plan

Medical Developments International (ASX: MVP) (**Company**) advises that it has today successfully completed its Share Purchase Plan (**SPP**) that has resulted in the issue of 1,868,703 fully paid ordinary shares in the Company at a price of \$4.00 per fully paid ordinary share, raising \$7.475 million (before costs).

The Company is delighted with the response and has decided not to scale back the applications.

The SPP shares were issued today and trading of the new shares will commence tomorrow. The holding statements will be dispatched to shareholders on 21 September 2018.

Enquiries:

David Williams  
Chairman  
Medical Developments International Ltd  
+61 (0) 414 383 593

John Sharman  
Chief Executive Officer  
Medical Developments International Ltd  
+61 (3) 9547 1888

### **About PENTHROX®**

PENTHROX® (methoxyflurane) is the only small, lightweight, handheld, fast-acting, inhaled analgesic that is self-administered under the supervision of the treating healthcare practitioner, indicated for the short-term relief of moderate to severe pain, associated with trauma or interventional medical procedures, in conscious adult patients. PENTHROX® provides rapid, effective pain relief in 5 minutes, with no need for needles and is not classified as an opioid. PENTHROX® allows patients to control their own pain relief by moderating the amount of PENTHROX® inhaled<sup>1</sup>.

### **About Medical Developments International Ltd**

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Pentrox®, a fast-acting trauma & emergency pain relief product. Pentrox is now approved in over 35 countries including 25 in the EU, Canada, New Zealand, South Africa and the Company expects to be selling into the majority of those countries in FY19. Locally, Pentrox continues its long-established use in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Force, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.